DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Enzalutamide + External Beam Rt For Prostate

Phase 2

Completed

Conditions: Intermediate Risk Prostate Cancer

Interventions: Drug: Enzalutamide
Radiation: External Beam Radiation

First Posted Date: 2014-01-07

Last Posted Date: 2023-05-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT02028988

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

Phase 2

Completed

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: abiraterone acetate

First Posted Date: 2013-12-31

Last Posted Date: 2025-04-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02025010

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States

and more 5 locations

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1

Completed

Conditions: KRAS Mutant Non-Small Cell Lung Cancer
Solid Tumors

Interventions: Drug: Palbociclib
Drug: PD-0325901

First Posted Date: 2013-12-30

Last Posted Date: 2024-03-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT02022982

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

PET/CT-Assessment of Liver Tumor Ablation

Not Applicable

Completed

Conditions: Liver Neoplasms
Liver Tumor

Interventions: Diagnostic Test: N-13 ammonia or F-18 fluorodeoxyglucose
Diagnostic Test: PET scan

First Posted Date: 2013-12-23

Last Posted Date: 2020-03-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT02018107

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2013-11-13

Last Posted Date: 2025-04-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 147

Registration Number: NCT01982448

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Indiana University- Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 17 locations

Healthy Living After Cancer: Weight Management Pilot Study

Not Applicable

Completed

Conditions: Weight Loss Program After Cancer Diagnosis

Interventions: Behavioral: Immediate Weight Loss Program Group
Behavioral: Delayed Weight Loss Program Group

First Posted Date: 2013-11-08

Last Posted Date: 2016-06-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT01978899

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Tivozanib As Maintenance Therapy In GYN

Phase 2

Terminated

Conditions: Primary Peritoneal Carcinoma
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: Tivozanib

First Posted Date: 2013-10-30

Last Posted Date: 2017-06-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01972516

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Panobinostat
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Bortezomib

First Posted Date: 2013-10-18

Last Posted Date: 2021-09-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT01965353

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

RPFNA Assessment of Exercise Effect in Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Exercise Intervention

First Posted Date: 2013-10-11

Last Posted Date: 2014-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01961128

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Early Changes In Multiparametric MRI In Prostate Cancer

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Device: MRI
Other: PSA Blood Test

First Posted Date: 2013-10-10

Last Posted Date: 2020-06-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01959542

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy